Article

SARcode reports phase III results for lifitegrast

SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
January 16th 2025

Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

How food choices may affect non-refractive visual impairment
January 16th 2025

How food choices may affect non-refractive visual impairment

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

RhyGaze secures Series A financing of $86 million to further novel gene therapy
January 15th 2025

RhyGaze secures Series A financing of $86 million to further novel gene therapy

Ashvattha Therapeutics secures $50M in financing to advance clinical trials
January 15th 2025

Ashvattha Therapeutics secures $50M in financing to advance clinical trials

© 2025 MJH Life Sciences

All rights reserved.